Last year saw the largest loss of revenue yet from major drugs due to patent expiries, but a continuation of 2011's higher level of drug approvals and new initiatives to address R&D challenges provide hope for the future.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Tse, M., Kirkpatrick, P. 2012 in reflection. Nat Rev Drug Discov 12, 8–10 (2013). https://doi.org/10.1038/nrd3927
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3927